Filing Flows › Seres Therapeutics (MCRB) › Q3 2026
Seres Therapeutics (MCRB) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Seres Therapeutics (MCRB) reported revenue of $593K for the third quarter 2026 (Q3 2026), +69% from a year earlier and -19% from the quarter before.
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $593K | -19% | +69% |
| Operating profit | −$16.2M | — | — |
| Net earnings | −$16.3M | -456% | -299% |
| Operating cash flow | −$10.5M | — | -575% |
What changed
Revenue was $593K in Q3 2026, up 69% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $16.2M, an operating margin of -2723.8%. Total costs fell 27% while revenue rose 69%. The fastest-growing cost line was Other operating costs (+675%). The quarter ended with a net loss of $16.3M, after a profit of $4.6M the previous quarter.
Operating cash flow was −$10.5M. Non-cash charges added back $481K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $3.5M.
Questions
What was Seres Therapeutics' revenue in the third quarter 2026?
Seres Therapeutics (MCRB) reported revenue of $593K for the third quarter 2026 (Q3 2026), +69% from a year earlier and -19% from the quarter before.
Source: Seres Therapeutics 10-Q on SEC EDGAR.